$LPCN
Lipocine Inc.

2014 Q2 Form 10-Q Financial Statement

#000114420414049314 Filed on August 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2013 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $710.0K
YoY Change 46.48% 1083.33%
% of Gross Profit
Research & Development $5.974M $443.9K
YoY Change 1245.89%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $7.010M $1.373M
YoY Change 410.45% 2188.69%
Operating Profit -$7.010M -$1.373M
YoY Change 410.45%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $40.00K $0.00
YoY Change
Pretax Income -$6.972M -$1.373M
YoY Change 407.94% 2187.54%
Income Tax $0.00 $182.00
% Of Pretax Income
Net Earnings -$6.972M -$1.373M
YoY Change 407.87% 2187.85%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55 -$0.31
Diluted Earnings Per Share -$0.55 -$0.31
COMMON SHARES
Basic Shares Outstanding 12.77M shares 4.456M shares
Diluted Shares Outstanding 12.77M shares 4.456M shares

Balance Sheet

Concept 2014 Q2 2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.16M $0.00
YoY Change
Cash & Equivalents $34.16M $3.606M
Short-Term Investments
Other Short-Term Assets $1.270M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $35.44M $0.00
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $24.60K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.75K
YoY Change
Total Long-Term Assets $48.36K $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $35.44M $0.00
Total Long-Term Assets $48.36K $0.00
Total Assets $35.49M $0.00
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $641.8K $20.00K
YoY Change 3109.01%
Accrued Expenses $1.029M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.670M $20.00K
YoY Change 8250.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.670M $20.00K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.670M $20.00K
YoY Change 8251.86%
SHAREHOLDERS EQUITY
Retained Earnings -$60.10M
YoY Change
Common Stock $1.278K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $40.71K
YoY Change
Treasury Stock Shares 5.710K shares
Shareholders Equity $33.82M -$20.00K
YoY Change
Total Liabilities & Shareholders Equity $35.49M $0.00
YoY Change

Cashflow Statement

Concept 2014 Q2 2013 Q2
OPERATING ACTIVITIES
Net Income -$6.972M -$1.373M
YoY Change 407.87% 2187.85%
Depreciation, Depletion And Amortization $10.00K $10.00K
YoY Change 0.0%
Cash From Operating Activities -$7.370M -$1.720M
YoY Change 328.49% 3340.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $20.00K $0.00
YoY Change
Cash From Investing Activities $20.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -260.0K -50.00K
YoY Change 420.0% -225.0%
NET CHANGE
Cash From Operating Activities -7.370M -1.720M
Cash From Investing Activities 20.00K 0.000
Cash From Financing Activities -260.0K -50.00K
Net Change In Cash -7.610M -1.770M
YoY Change 329.94% 17600.0%
FREE CASH FLOW
Cash From Operating Activities -$7.370M -$1.720M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$7.370M -$1.720M
YoY Change 328.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2724441 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12238784 USD
CY2013Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1372707 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4455790 shares
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12749355 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1027021 USD
CY2014Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
641801 USD
CY2014Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24602 USD
CY2014Q2 us-gaap Liabilities
Liabilities
1670371 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2013Q4 us-gaap Assets
Assets
46107522 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
256754 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1283775 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
45263698 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
770030 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28794 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000 USD
CY2014Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60103185 USD
CY2014Q2 us-gaap Stockholders Equity
StockholdersEquity
33815153 USD
CY2014Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35485524 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6971627 USD
CY2013Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4455790 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12770391 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34164006 USD
CY2014Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1273163 USD
CY2014Q2 us-gaap Assets Current
AssetsCurrent
35437169 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
46033728 USD
CY2014Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
23753 USD
CY2014Q2 us-gaap Assets
Assets
35485524 USD
CY2014Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1028570 USD
CY2014Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
93957772 USD
CY2014Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q2 us-gaap Common Stock Value
CommonStockValue
1278 USD
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6971627 USD
CY2013Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4455790 shares
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12770391 shares
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2724441 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12238784 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1372707 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4455790 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12749355 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2724441 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12238784 USD
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1372707 USD
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2014Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1025467 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1019409 USD
CY2014Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12780382 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12668393 shares
CY2014Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12774672 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12668393 shares
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1933480 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
142520 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
285756 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
294373 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
303119 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
51903 USD
CY2014Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1077671 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
178000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
177000 USD
CY2013Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
91000 USD
CY2014Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
77000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
598486 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1214126 USD
CY2013Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
118180 USD
CY2014Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
168740 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y14D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0193 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7309 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1264345 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
37500 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20205 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3621 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1112 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1276907 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1044333 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.03
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.73
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.84
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.38
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.83
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y25D
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3683983 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M10D
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3423100 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1088967 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9342829 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
443857 USD
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5973829 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1419663 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2959356 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
712627 USD
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1035733 USD
us-gaap Operating Expenses
OperatingExpenses
2725358 USD
us-gaap Operating Expenses
OperatingExpenses
12302185 USD
CY2013Q2 us-gaap Operating Expenses
OperatingExpenses
1373212 USD
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
7009562 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2725358 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12302185 USD
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1373212 USD
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7009562 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1211 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
63401 USD
CY2013Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
687 USD
CY2014Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
37935 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-2724147 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-12238784 USD
CY2013Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1372525 USD
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6971627 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
294 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182 USD
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-6971627 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-1372707 USD
us-gaap Net Income Loss
NetIncomeLoss
-2724441 USD
us-gaap Net Income Loss
NetIncomeLoss
-12238784 USD
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6971627 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.20
CY2014Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
687000 USD
CY2013Q2 lpcn Percentage Of Fee To Be Received
PercentageOfFeeToBeReceived
0.2 pure
CY2013Q2 lpcn Maximum Proceeds From Affiliates Under License Agreement
MaximumProceedsFromAffiliatesUnderLicenseAgreement
10000000 USD
CY2013Q2 lpcn Description Of Terms Of Service Agreement
DescriptionOfTermsOfServiceAgreement
Under the service agreement, the Company will provide facilities and up to 10 percent of the services of certain employees to Spriaso for a period of up to 12 months with an ability to extend for another six months.
us-gaap Depreciation And Amortization
DepreciationAndAmortization
10483 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6058 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
3815 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
598486 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1214126 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
92732 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-12306 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
503133 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
458579 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-385220 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
16901 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
771816 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
294 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1716309 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11135137 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1206 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1866 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1206 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
19381 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1770615 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-11099692 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5377114 USD
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3606499 USD
dei Document Period End Date
DocumentPeriodEndDate
2014-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Registrant Name
EntityRegistrantName
Lipocine Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001535955
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
LPCN
CY2014Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12786672 shares
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16064 USD
CY2014Q2 us-gaap Treasury Stock Value
TreasuryStockValue
40712 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
lpcn Reverse Merger Costs
ReverseMergerCosts
216728 USD
lpcn Reverse Merger Costs
ReverseMergerCosts
0 USD
CY2013Q2 lpcn Reverse Merger Costs
ReverseMergerCosts
216728 USD
CY2014Q2 lpcn Reverse Merger Costs
ReverseMergerCosts
0 USD
us-gaap Payments For Deposits
PaymentsForDeposits
0 USD
us-gaap Payments For Deposits
PaymentsForDeposits
-21247 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
53100 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-53100 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16064 USD
us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
44689 USD
us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
40712 USD
CY2014Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
5710 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares

Files In Submission

Name View Source Status
0001144204-14-049314-index-headers.html Edgar Link pending
0001144204-14-049314-index.html Edgar Link pending
0001144204-14-049314.txt Edgar Link pending
0001144204-14-049314-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lpcn-20140630.xml Edgar Link completed
lpcn-20140630.xsd Edgar Link pending
lpcn-20140630_cal.xml Edgar Link unprocessable
lpcn-20140630_def.xml Edgar Link unprocessable
lpcn-20140630_lab.xml Edgar Link unprocessable
lpcn-20140630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v385173_10q.htm Edgar Link pending
v385173_ex31-1.htm Edgar Link pending
v385173_ex31-2.htm Edgar Link pending
v385173_ex32-1.htm Edgar Link pending
v385173_ex32-2.htm Edgar Link pending